# Hangzhou Zhongmei Huadong trials: 50

ClinicalTrials.gov lists 50 trials with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. as lead sponsor, 33 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.: 50 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 18, 2026 | NCT07828197 | A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Overweight and/or Obesity, Healthy Participants | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828197) |
| September 4, 2026 | NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | CRC, Colorectal Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805551) |
| August 31, 2026 | NCT07794397 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005... | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Obstructive Sleep Apnea (OSA) and Obesity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794397) |
| August 26, 2026 | NCT07787260 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005... | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Obstructive Sleep Apnea (OSA) and Obesity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787260) |
| July 13, 2026 | NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Mantle Cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697339) |
| July 6, 2026 | NCT07683806 | Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Seborrheic Dermatitis | 309 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683806) |
| June 10, 2026 | NCT07638891 | A Study of HDM2020 in Patients With Advanced Sq-NSCLC | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Squamous Non-small Cell Lung Cancer(NSCLC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638891) |
| June 2, 2026 | NCT07621159 | A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Colorectal Cancer Metastatic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621159) |
| May 19, 2026 | NCT07594847 | A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Healthy Adult Subject | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594847) |
| April 30, 2026 | NCT07559240 | A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Overweight, Obese | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559240) |
| April 20, 2026 | NCT07539285 | A Study of HDM2024 in Participants With Advanced Solid Tumors | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539285) |
| April 14, 2026 | NCT07529782 | Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma and Other Plasma Cell Neoplasms | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529782) |
| April 13, 2026 | NCT07521631 | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Obesity | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521631) |
| March 30, 2026 | NCT07502001 | Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Overweight, Obesity | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502001) |
| February 18, 2026 | NCT07417306 | A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2... | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Type 2 Diabetes | 912 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417306) |
| February 6, 2026 | NCT07394114 | A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Type 2 Diabetes | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07394114) |
| January 30, 2026 | NCT07377591 | A Study of HDM2006 in Patients With Advanced Solid Tumor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377591) |
| January 22, 2026 | NCT07357831 | A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Completed | Plaque Psoriasis | 539 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357831) |
| January 9, 2026 | NCT07331389 | A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Overweight Subject, Healthy Subjects | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331389) |
| December 12, 2025 | NCT07279194 | Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Obesity & Overweight | 825 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279194) |
| December 10, 2025 | NCT07274085 | A Phase 1 Study of HDM2017 in Advanced Solid Tumors | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Solid Tumors | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07274085) |
| November 24, 2025 | NCT07244003 | Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 4 | Recruiting | T2DM (Type 2 Diabetes Mellitus) | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244003) |
| September 25, 2025 | NCT07193459 | Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Type 2 Diabetes | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193459) |
| August 15, 2025 | NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124936) |
| August 12, 2025 | NCT07116928 | Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | 1,244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116928) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 3 | 16 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 24 |
| Not yet recruiting | 9 |
| Completed | 9 |
| Unknown | 7 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 11 |
| Diabetes Mellitus, Type 2 | 10 |
| Overweight | 7 |
| Sleep Apnea, Obstructive | 2 |
| Carcinoma, Ovarian Epithelial | 1 |
| Fallopian Tube Neoplasms | 1 |
| Lymphoma | 1 |
| Hematologic Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Kidney Diseases | 1 |
| Renal Insufficiency | 1 |
| Neoplasms, Plasma Cell | 1 |
| Multiple Myeloma | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Dermatitis, Seborrheic | 1 |
| Renal Insufficiency, Chronic | 1 |
| Dermatitis, Atopic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Sushi restaurants in the United States](https://specstream.ai/data/businesses/sushi-restaurants/united-states)
- [Soup restaurants in the United States](https://specstream.ai/data/businesses/soup-restaurants/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
